# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Conduit intends to initiate Phase 2a clinical trials to evaluate AZD1656 for the treatment of systemic lupus erythematosus (inc...
Conduit Pharmaceuticals shares traded higher by over 50% early Tuesday. The company announced it received patent approval for i...